Entero Healthcare Solutions Limited has informed the Exchange regarding Change in Auditors of the company.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare Solutions held its Board Meeting on May 25, 2026, approving the audited standalone and consolidated financial results for Q4 and FY2026. Standalone FY2026 revenue was Rs 3,482.41 million with net profit of Rs 268.75 million, versus Rs 5,230.39 million revenue and Rs 191.81 million profit in FY2025. Consolidated FY2026 revenue was Rs 65,912.12 million with net profit of Rs 1,458.40 million, up from Rs 51,352.85 million and Rs 1,074.34 million in the prior year. The Board re-appointed three Independent Directors (Sujesh Vasudevan, Rajesh Shashikant Dalal, Sandhya Gadkari Sharma) for a second term of five years, granted 7,300 fresh ESOPs, and allotted 7,240 equity shares to employees upon ESOP exercise. An acquisition of Vishal Surgicals and Vishal Surgicals & Medicals via subsidiary Sai Pharma Distributors Private Limited through a Slump Sale agreement was also approved. The 8th AGM is scheduled for August 19, 2026.
Strong financial performance with consolidated revenue and profit growth year-on-year, though standalone revenue declined due to business restructuring. Multiple acquisitions and ESOP grants signal continued expansion, which could be positive for the stock.